The global asthma and COPD therapies market will reach $41.23bn in 2017 predicts visiongain

LONDON - Oct. 4, 2013 - PRLog -- A new report by Visiongain (http://www.visiongain.com) predicts the market for asthma (http://www.visiongain.com/Sector/8/Pharma) and COPD therapies will reach $41.23bn in 2017. That industry generated $34.15bn in 2012, and its revenues will show strong growth to 2023. That sales forecast and others appear in Asthma and COPD Therapies: World Market 2013-2023 (http://www.visiongain.com/Report/1109/Asthma-and-COPD-Therapies-World-Market-2013-2023). Visiongain is a business information provider based in London, UK.

In 2012, asthma and COPD therapies dominated the global respiratory therapies market.

Traditionally, the asthma and COPD therapies market has been dominated by few key products and two major companies: GlaxoSmithKline and Boehringer Ingelheim. However, as established drugs like Singulair go off-patent, the market faces generic competition as new companies enter the market with advanced inhaler devices. Additionally, multiple branded pharmaceutical companies like AstraZeneca, Novartis, and Roche are striving to increase their share of this rapidly growing segment, through new pipeline drug and/or acquisitions. The overall market continues to grow and accommodate competition, with potential for multiple blockbuster drugs, on account of a segregated patient subgroups and an overall growing patient population. Also, educational measures, increasing profile of such diseases, improving patient management techniques like telehealth and advancing inhaler technologies will benefit this industry as the market begins to move towards more personalised-therapy. The asthma and COPD therapies accounted for 76% of the global respiratory market in 2012, as combination drugs continue to dominate the market.

Rodrigo Gutierrez Gamboa, a senior pharmaceutical industry analyst in visiongain said: “The respiratory diseases market has always been a lucrative market for pharmaceutical companies. The primary factors for this growth are the rising prevalence of asthma and COPD, an aging population and expensive treatment options.

“The asthma and COPD drug market has expanded in recent years and we expect the market to show significant growth over the next decade, owing primarily to a greater demand for new drugs with greater efficacy. The COPD market will grow at a higher rate as it is fairly untapped. Many of the leading companies are increasing their focus on COPD, with new combination drugs and novel agents expected to be launched over the coming years. The asthma market is, however, approaching maturity with multiple established products going off-patent. This will create significant opportunities for generic manufacturers over the next five years.

“Nevertheless, we expect the overall market to shift to a more dynamic and competitive pattern as a number of new players enter this area with varying strategies ranging from using the same drug in a different inhaler, to combining two off-patent drugs targeting different subgroups of patients, based on severity or phenotype.